Crispr Therapeutics AG (NASDAQ:CRSP) COO Lawrence Otto Klein sold 25,000 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $60.40, for a total value of $1,510,000.00. Following the transaction, the chief operating officer now owns 45,000 shares in the company, valued at $2,718,000. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Shares of NASDAQ CRSP traded down $2.18 during mid-day trading on Wednesday, hitting $57.37. 1,215,046 shares of the stock traded hands, compared to its average volume of 1,017,390. Crispr Therapeutics AG has a 52 week low of $32.30 and a 52 week high of $74.00. The company has a market cap of $3.78 billion, a price-to-earnings ratio of 79.40 and a beta of 2.26. The stock has a fifty day moving average price of $47.47 and a 200-day moving average price of $54.21.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, April 28th. The company reported ($1.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.05) by ($0.10). The firm had revenue of $0.16 million for the quarter, compared to the consensus estimate of $3.04 million. Crispr Therapeutics had a net margin of 15.73% and a return on equity of 6.54%. The company's revenue for the quarter was down 52.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.93) earnings per share. Analysts forecast that Crispr Therapeutics AG will post -4.51 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the business. Webster Bank N. A. purchased a new position in Crispr Therapeutics during the fourth quarter valued at $26,000. NEXT Financial Group Inc raised its stake in Crispr Therapeutics by 606.4% during the first quarter. NEXT Financial Group Inc now owns 883 shares of the company's stock valued at $37,000 after buying an additional 758 shares during the last quarter. Signaturefd LLC raised its stake in Crispr Therapeutics by 41.4% during the first quarter. Signaturefd LLC now owns 940 shares of the company's stock valued at $40,000 after buying an additional 275 shares during the last quarter. Sandy Spring Bank purchased a new position in Crispr Therapeutics during the first quarter valued at $40,000. Finally, Advisory Services Network LLC raised its stake in Crispr Therapeutics by 146.0% during the fourth quarter. Advisory Services Network LLC now owns 674 shares of the company's stock valued at $41,000 after buying an additional 400 shares during the last quarter. Institutional investors and hedge funds own 51.99% of the company's stock.

Several equities analysts recently issued reports on the company. BidaskClub upgraded Crispr Therapeutics from a "hold" rating to a "buy" rating in a research report on Thursday, May 7th. Citigroup raised their price target on Crispr Therapeutics from $28.00 to $31.00 and gave the stock a "sell" rating in a research report on Wednesday, March 4th. Needham & Company LLC assumed coverage on Crispr Therapeutics in a research report on Wednesday, April 29th. They set a "buy" rating and a $84.00 price target on the stock. Zacks Investment Research lowered Crispr Therapeutics from a "buy" rating to a "hold" rating and set a $56.00 price target on the stock. in a research report on Friday, April 24th. Finally, Stifel Nicolaus assumed coverage on Crispr Therapeutics in a research report on Wednesday, March 4th. They issued a "hold" rating and a $52.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and thirteen have assigned a buy rating to the company's stock. The stock has an average rating of "Buy" and a consensus target price of $73.11.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Story: What causes a recession?

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

10 Great Cheap Stocks to Buy Now for Under $10

As the P/E ratios of most S&P 500 companies look very expensive and the stock market continues to regularly hit new all-time highs, it's very difficult for investors to find cheap stocks to buy now.

This goes for both share price, since most stocks are trading higher on a per-share basis, and valuation relative to earnings. Right now, the typical S&P 500 company is trading at about 25 times forward-looking earnings. Historically, S&P 500 companies have traded at about 15 times earnings in more normal markets.

While the S&P 500 as a whole is expensive, there are still a handful undervalued stocks that are trading at less than $10.00 per share. Value investing opportunities for value exist if you know where to look. Putting together a list of cheap stocks to buy now requires looking into some smaller, riskier, unloved or undiscovered parts of the market. These low-priced stocks might not look especially attractive today, but long-term investors stand to profit if they are willing to be patient and hold onto shares of these companies through multiple market cycles.

Some of these companies are great investing ideas because they're too small and too risky to attract the interest of most mutual funds and Wall Street money managers. Others have been beaten up by the market after a period of slowing earnings and profits, but are now trying to turn around and bounce back.

In this list, you might find marijuana stocks, dividend-paying stocks, large-cap stocks, growth stocks, small-cap stocks, and even some bitcoin stocks. While these low-priced stocks have a lot of differences, these 10 stock picks all share a common characteristic, a super-low share price of $10.00 or less.

View the "10 Great Cheap Stocks to Buy Now for Under $10".



Source link